Navigation Links
QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes
Date:1/23/2008

NEW YORK, Jan. 23 /PRNewswire/ -- QED International Associates, Inc., administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange-Traded Funds, today announced that effective at the opening of trading on Monday January 28, 2008 Regeneron Pharmaceuticals Inc. (Nasdaq: REGN) will replace MGI Pharma, Inc. (Nasdaq: MOGN) in the HealthShares(TM) Composite Index. MGI Pharma is being acquired by Eisai Pharma of Japan (Tokyo, TSE:4523).

Eisai Pharma will replace MGI Pharma in the HealthShares(TM) Cancer Index, and Dr. Reddy's Laboratories, Ltd (NYSE: RDY) will replace MGI Pharma in the HealthShares(TM) Neuroscience Index.

The Composite Index consists of the 80 largest companies by market capitalization that are engaged in healthcare, life sciences and/or biotechnology that are part of the 20 Composite eligible Indexes.

Companies included in the HealthShares(TM) Cancer Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of cancers. They generally include those with substantial revenues and significant research and development programs.

Companies included in the HealthShares(TM) Neuroscience Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of neurological and psychiatric disorders including, but not limited to, Alzheimer's, Parkinson's, Huntington's, schizophrenia, anxiety, depression, epilepsy, pain and sleep disorders.

The weightings for Regeneron Pharmaceuticals in the HealthShares(TM) Composite Index, Eisai Pharma in the HealthShares(TM) Cancer Index and Dr. Reddy's Laboratories, Ltd. in the HealthShares(TM) Neuroscience Index will be identical to those of companies being removed from their indexes on the effective date.

About QED International Associates

QEDI International, based in New York, is a leading financial industry consulting firm specializing in quantitative modeling and the design, development and maintenance of indexes and Exchange Traded Funds. For more information, visit the company's website at http://www.qedinternational.com


'/>"/>
SOURCE QED International Associates, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tasker Products to Showcase Tasker Blue at International Poultry Expo
2. Society for Biological Engineering Holds First International Conference on Stem Cell Engineering
3. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
4. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
5. Carbon offset warning from international team of scientists
6. Palomar and Q-MED AB Enter Into International Distribution Agreement
7. International Association of Fire Fighters (IAFF) Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO-Oximetry
8. International team identifies 480 genes that control human cell division
9. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
10. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
11. Baxter International Fourth Quarter 2007 Financial Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... CA (PRWEB) , ... October ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed ... bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who made ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... will be hosting a Webinar titled, “Pathology is going digital. Is your lab ... digital pathology adoption best practices and how Proscia improves lab economics and realizes ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, ... security market and how smart safety and security products impact the competitive ... Parks Associates: Smart Home Devices: Main ... "The residential security market has experienced continued ...
Breaking Biology Technology:
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Biology News(10 mins):